Circadian Variations, Continuous Positive Airway Pressure, Prostaglandins, Sleep Apnea
Conditions
Keywords
Sleep apnea, CPAP, Prostaglandins, Circadian variations
Brief summary
The purpose of this study is to evaluate the associations of circadian variations, sleep architecture, hypertension and prostanoids in the patients with sleep apnea. In addition, the patients introduced to continuous positive airway pressure(CPAP) treatment, the effects of CPAP are also evaluated.
Detailed description
Obstructive sleep apnea (OSA) is characterized by repetitive episodes of upper airway obstruction during sleep that provoke frequents arousals, sleep fragmentation, oxygen desaturation, and excessive daytime sleepiness. OSA may contribute to the development of systemic hypertension, cardiovascular disease. Many studies has reported a crucial role for the prostaglandin D system in sleep regulation. In addition, it has been described urinary or blood levels of prostaglandins was higher in the patients with hypertension, diabetes mellitus, and these values were associated with the severity of coronary artery disease. However, the relation between alterations of prostaglandin D system and sleep architecture, sleepiness, and clinical outcomes such as hypertension, arteriosclerosis in the patients with OSA are not known. Additionally, after CPAP treatment, we will investigate the association between change of prostaglandin system and sleep architecture, sleepiness, clinical outcomes.
Interventions
DEVICECPAP treatment
maintains upper airway patency and minimizes the obstructive events
Sponsors
Kyoto University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects on admission for sleep study under the Respiratory Care and Sleep Control Medicine, Kyoto University Hospital. * Subjects diagnosed with OSA (apnea hypopnea index \>=5/hour) by overnight polysomnography.
Exclusion criteria
* Subjects treating for acute infections or malignancy. * Subjects with severe cardiovascular disease, diabetes,and renal failure. * Subjects taking nonsteroidal anti-inflammatory drugs, steroids or immunosuppressants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostaglandins in the urine and blood | baseline, and 2days, 3 months after CPAP |
Secondary
| Measure | Time frame |
|---|---|
| polysomnography measurements | baseline, and 2days, 3 months after CPAP |
| sleepiness and health-related quality of life | baseline, and 2days, 3 months after CPAP |
| Clinical measurements (blood pressure, heart rate, sympathetic activity etc) | baseline, and 2days, 3 months after CPAP |
| serum and urinary biomarker (inflammation, oxidative stress etc.) | baseline, and 2days, 3 months after CPAP |
| endothelial function | baseline, and 2days, 3 months after CPAP |
Countries
Japan
Outcome results
None listed